SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-21-003558
Filing Date
2021-05-17
Accepted
2021-05-17 07:11:30
Documents
3
Period of Report
2021-05-11
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_051721.htm 8-K 13513
2 PRESS RELEASE exh_991.htm EX-99.1 7179
3 exh991small_1.jpg GRAPHIC 3298
  Complete submission text file 0001171843-21-003558.txt   26601
Mailing Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5
Business Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5 450-686-4555
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 21927521
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences